RT Journal Article SR Electronic T1 Comparison of Etanercept Monotherapy and Combination Therapy with Methotrexate in Psoriatic Arthritis: Results from 2 Clinical Trials JF The Journal of Rheumatology JO J Rheumatol FD The Journal of Rheumatology SP jrheum.151290 DO 10.3899/jrheum.151290 A1 Bernard Combe A1 Frank Behrens A1 Neil McHugh A1 Fiona Brock A1 Urs Kerkmann A1 Blerina Kola A1 Gaia Gallo YR 2016 UL http://www.jrheum.org/content/early/2016/04/22/jrheum.151290.abstract AB Objective To evaluate the clinical/functional outcomes associated with etanercept (ETN) monotherapy versus combination therapy in psoriatic arthritis (PsA). Methods Data from patients with PsA who received ETN alone (n = 322) or combined with methotrexate (MTX; n = 152) for 24 weeks in 2 placebo-controlled clinical trials were summarized across studies. Results Similar proportions of patients in the monotherapy and combination therapy groups achieved the PsA Response Criteria (80% and 83%) and the American College of Rheumatology improvements of 20% (ACR20; both 70%); numerically higher proportions receiving monotherapy achieved ACR50 (55% vs 48%) and ACR70 (35% vs 27%). Little between-group difference was observed in the 28-joint Disease Activity Score with C-reactive protein, the Psoriasis Area and Severity Index, and the Health Assessment Questionnaire–Disability Index improvement. Conclusion ETN with and without MTX provided similar benefits in active PsA.